- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01670708
HOPE Demonstration Field Experiment Multisite Evaluation
December 13, 2017 updated by: RTI International
Multisite Evaluation of the Honest Opportunity With Enforcement Demonstration Field Experiment
The purpose of the Multisite Evaluation of the Honest Opportunity Probation with Enforcement Demonstration Field Experiment (the HOPE DFE Evaluation) is to conduct a randomized control trial (RCT) replication of the original Hawaii HOPE program and evaluation.
The HOPE program provides strict oversight of probationers through a HOPE Court judge and intensive probation supervision, including random drug testing, coupled with swift and certain sanctions in response to positive results on random drug tests and other violations of conditions of supervision.
The HOPE DFE Evaluation is being conducted among probation populations in four sites and will identify the effectiveness of swift and certain sanctions on targeted outcomes, both primary (appointment no-shows, positive urine tests, re-arrest rates) and secondary (revocation rates, jail days served, prison days sentenced).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The Multisite Evaluation of the Honest Opportunity Probation with Enforcement Demonstration Field Experiment (the HOPE DFE Evaluation) has four goals: (1) Design and implement a randomization process in each of the four DFE sites; (2) Conduct a comprehensive process evaluation to assess implementation fidelity and identify lessons learned that will enhance future replications; (3) Conduct a rigorous experimental outcome evaluation to determine the effect of the HOPE model and its components on individual probation outcomes; and (4) Conduct a cost evaluation to assess the cost effectiveness of HOPE.
The RCT will involve identifying in each of four sites a pool of HOPE-eligible probationers who will be randomly assigned to HOPE or to probation as usual (PAU).
The evaluation will randomly assign approximately 400 eligible probationers to HOPE or PAU in each of the four sites for a total sample size of 1,600 (800 HOPE and 800 PAU).
Criteria identifying the HOPE-eligible target population and procedures to identify that population in a timely fashion randomly assigning HOPE-eligible Probationers to HOPE or PAU have been identified.
Random assignment will be accomplished using evaluation-provided forms that include study identification numbers and the random assignment that is covered by a scratch-off label.
The assignment will be revealed only after the individual has been provided the opportunity to participate in the evaluation and, with consent, completed the baseline interview.
The process evaluation/fidelity assessment component will document the extent to which each program conforms to the HOPE model; document the barriers, challenges, facilitators, and lessons learned during implementation to fill gaps in the knowledge base as to what is required to set up a HOPE program; and provide evidence as to the generalizability and sustainability of HOPE programs.
This component will also document the PAU control conditions in each site and will assess implementation fidelity of evidence-based drug treatment programs.
Implementation and process measures will be collected through stakeholder interviews; observation of initial warning hearings and court appearances; and review of court, probation, and HOPE project records.
The process evaluation will also document the PAU practices to identify intervention differences among the control groups and to provide an opportunity to measure changes in practices that could signal contamination of the control arm.
Fidelity assessments of drug treatment programs will be conducted using the Correctional Program Checklist.
The outcome study will assess whether HOPE participation improves appointment compliance, drug test results, rearrest rates, revocation rates, jail days served, and prison days sentenced.
In addition, the evaluation will determine whether HOPE participation changes potential mediators including criminal thinking/attitudes, perceptions of control and justice system fairness and legitimacy, dynamic recidivism risk factors, and employment and housing stability.
For the outcome study, administrative data will provide information on appointment compliance, drug test results, re-arrests, violations, revocations, and jail and prison days for all HOPE and PAU evaluation participants.
Interview data will be collected from evaluation participants at evaluation enrollment and 6 months post-enrollment on measures that will facilitate understanding of the nature of individual change associated with HOPE participation.
All HOPE-eligible Probationers who consent to study participation will complete an audio computer assisted self interview (ACASI) at baseline and 6 months post baseline; a random sample of those completing ACASI baseline interviews will be asked to participate in a twice-weekly series of mini-interviews (telephone-ACASI or T-ACASI).
Non-incarcerated individuals are being offered $20 equivalent to complete the ACASI interview.
Random drug tests on a subsample of HOPE and PAU evaluation participants will be conducted in conjunction with the 6-month post-enrollment interviews to provide a common measure of current drug use.
Study Type
Interventional
Enrollment (Actual)
1504
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Benton, Arkansas, United States
- Court and Probation Office, Saline County
-
-
Massachusetts
-
Salem, Massachusetts, United States
- Salem County Probation Office, Massachusetts Salem District Court, Essex County Superior Court
-
-
Oregon
-
Oregon City, Oregon, United States
- Court and Probation Office
-
-
Texas
-
Fort Worth, Texas, United States
- Court and Probation Office, Tarrant County
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult probationers assessed as high risk for failure on probation (e.g., high likelihood of new arrest, failure to comply with conditions) who live within the geographic boundaries of the study site with at least 11.5 months remaining on their probation sentence
Exclusion Criteria:
- Juveniles
- live outside geographic boundaries
- assigned to specialized probation caseloads (e.g., sex offender, DUI, mental health)
- non-English speaking in some sites
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HOPE
Participation in HOPE program
|
HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
|
Active Comparator: Probation as Usual
Participation in probation as usual
|
Probation officer supervises following standard protocols.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Illegal drug use
Time Frame: 6 months
|
Multiple measures to include percent positive for (1) marijuana, (2) cocaine, (3) heroin, (4) methamphetamine, and (5) any illegal drug on an oral swab drug test administered in conjunction with the 6 month follow-up interview (subjects in the community, i.e. not jailed or institutionalized, only).
|
6 months
|
Rearrest
Time Frame: 6 Months
|
Multiple measures to include (1) percent arrested within 6 months of baseline; (2) time to first (and subsequent) arrests following baseline; (3) number of arrests following baseline (variable follow-up period depending upon baseline date); (4) number of arrests within 6 months of baseline; and (5) percent arrested for (a) violent, and (b) property
|
6 Months
|
Rearrest
Time Frame: 12 months
|
Multiple measures to include (1) percent arrested within 12 months of baseline; (2) time to first (and subsequent) arrests following baseline; (3) number of arrests following baseline (variable follow-up period depending upon baseline date); (4) number of arrests within 12 months of baseline; and (5) percent arrested for (a) violent, (b) property, and (c) drug offenses within 12 months of baseline.
|
12 months
|
Probation Appointment Compliance
Time Frame: 6 months
|
Number of missed appointments following baseline.
|
6 months
|
Probation Appointment Compliance
Time Frame: 12 months
|
Number of missed appointments following baseline.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Probation revocation
Time Frame: 6 months
|
Percent revoked from probation within 6 months following baseline.
|
6 months
|
jail days served
Time Frame: 6 months
|
Number of days served in jail within 6 months following baseline for (1) violation of conditions of probation; (2) arrest or charge for new offense; (3) sentence for new offense; and (4) total number of days.
|
6 months
|
Probation Revocation
Time Frame: 12 Months
|
Percent revoked from probation within 12 months following baseline.
|
12 Months
|
Jail Days Served
Time Frame: 12 months
|
Number of days served in jail within 12 months following baseline for (1) violation of conditions of probation; (2) arrest or charge for new offense; (3) sentence for new offense; and (4) total number of days.
|
12 months
|
Prison Days Sentenced
Time Frame: 6 months
|
Number of days sentenced to prison within 6 months following baseline for (1) probation revocation; (2) conviction for a new offense; and (3) total of revocation and new conviction.
|
6 months
|
Prison Days Sentenced
Time Frame: 12 months
|
Number of days sentenced to prison within 12 months following baseline for (1) probation revocation; (2) conviction for a new offense; and (3) total of revocation and new conviction.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pamela K Lattimore, PhD, RTI International
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2012
Primary Completion (Actual)
March 31, 2015
Study Completion (Actual)
March 31, 2015
Study Registration Dates
First Submitted
August 7, 2012
First Submitted That Met QC Criteria
August 20, 2012
First Posted (Estimate)
August 22, 2012
Study Record Updates
Last Update Posted (Actual)
December 15, 2017
Last Update Submitted That Met QC Criteria
December 13, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-RY-BX-0003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingSubstance Use | Substance Use Disorders | Substance DependenceUnited States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Opioid Use | Drug Use | Substance MisuseUnited States
-
Centre for Addiction and Mental HealthUniversity of Missouri, St. LouisCompletedSubstance Use Disorders | Alcohol Use DisorderCanada
-
Istanbul UniversityCompletedSubstance Use | Substance Use Disorders | Substance AbuseTurkey
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedPTSD | Alcohol Use Disorders | Substance Use DisordersUnited States
Clinical Trials on HOPE
-
Pepperdine UniversityUniversity of California, Los Angeles; University of California, IrvineCompleted
-
University Hospital, AngersUnknown
-
University of California, IrvineActive, not recruitingCOVID-19 VaccinationUnited States
-
The University of AkronNational Institute of Mental Health (NIMH); Butler Hospital; Summa Health SystemCompletedPost-Traumatic Stress Disorder | Battered WomenUnited States
-
Medical College of WisconsinEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingParent-Child Relations | Premature InfantsUnited States
-
University of ManitobaHealth Sciences Centre Foundation, ManitobaActive, not recruitingSuicidal Ideation | Suicide, Attempted | SuicideCanada
-
Memphis VA Medical CenterVirginia Commonwealth University; University of TennesseeActive, not recruitingTBI (Traumatic Brain Injury) | Dementia, Mixed | Dementia of Alzheimer TypeUnited States
-
Göteborg UniversityCompleted
-
The University of AkronBrown University; Summa Health System; Pacific Institute for Research and Evaluation and other collaboratorsCompleted